title: Etiology and prevention of pulmonary complications following beta-mimetic mediated tocolysis.
abstract: OBJECTIVE
  This study documents biological (haematocrit variations) and therapeutic parameters (salbutamol doses, volumes perfused) in two groups tocolysed with salbutamol, one with and the other without APO in order to define the risk factors linked to APO and to establish a standard protocol of management.
  
  
  METHODS
  This retrospective study includes data from 68 intravenous salbutamol tocolysis with four resulting APOs, carried out between January 1st, 1993 and December 31st, 1995.
  
  
  RESULTS
  There was an excessive level of salbutamol administered over 48 h in the complicated APO-group (122.5+/-52 mg) opposed to the non-APO group (44.9 21 mg) as well as an overload of perfused solute (3.1+/-1.11) versus (1.9+/-1.11). Blood hemodilution was demonstrated in the APO group with a decrease of haematocrit by over 10% between the admission and the control value. No other risk factor was found.
  
  
  CONCLUSIONS
  Tocolysis should be administered at the lowest possible perfusion rate with incremental doses as long as the heart rate stays under 120 beats/min and stopped after 48 h. Administration of maximal 11 of solute perfused/day is recommended. For the patient's follow-up we estimate daily input and output fluid to avoid hydric overload, and a daily control of haematocrit whose variation must be less than 10%.
authors.forename: A M
authors.initials: AM
authors.lastname: Bader
authors.forename: E
authors.initials: E
authors.lastname: Boudier
authors.forename: C
authors.initials: C
authors.lastname: Martinez
authors.forename: B
authors.initials: B
authors.lastname: Langer
authors.forename: J
authors.initials: J
authors.lastname: Sacrez
authors.forename: Y
authors.initials: Y
authors.lastname: Cherif
authors.forename: M
authors.initials: M
authors.lastname: Messier
authors.forename: G
authors.initials: G
authors.lastname: Schlaeder
mesh_terms: D000208:Acute Disease; D000318:Adrenergic beta-Agonists / Q000009:adverse effects* / Q000627:therapeutic use; D000328:Adult; D000420:Albuterol / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006339:Heart Rate; D006400:Hematocrit; D006801:Humans; D011247:Pregnancy; D011654:Pulmonary Edema / Q000139:chemically induced* / Q000517:prevention & control*; D012189:Retrospective Studies; D013997:Time Factors; D015145:Tocolysis; D015149:Tocolytic Agents / Q000009:adverse effects*
chemical_list: D000318:Adrenergic beta-Agonists; D015149:Tocolytic Agents; D000420:Albuterol